TABLE 2.
Antiviral activities of antifungal drugs against different HCMV strains in different cell types
| HCMV strain | Cell type | Antiviral activity EC50 (μM)a |
|||
|---|---|---|---|---|---|
| ECZ | MCZ | PCZ | Controlb | ||
| TB40-UL32-EGFP | HFF | 4.5 ± 0.7 | 3.8 ± 0.4 | 3.5 ± 1.8 | 3.5 ± 0.7 |
| VR1814 | HFF | 3.9 ± 2.1 | 4.3 ± 1.1 | 3.5 ± 0.7 | 2.3 ± 1.3 |
| 388438U | HFF | NDc | ND | 3.2 ± 0.4 | 3.2 ± 0.8 |
| 759rD100 | HFF | 4.3 ± 1.1 | 4.5 ± 1.8 | 2.6 ± 1.2 | 75 ± 12 |
| GDGrP53 | HFF | 3.4 ± 0.9 | 2.6 ± 0.3 | 3.5 ± 1.1 | 1.9 ± 1.8 |
| PFArD100 | HFF | 4.2 ± 0.1 | 3.7 ± 0.6 | 4.8 ± 1.5 | 250 ± 18 |
| TR | HFF | ND | ND | 3.7 ± 1.3 | ND |
| TR | ARPE-19 | ND | ND | 4.2 ± 1.8 | ND |
| TR | HMVEC | ND | ND | 4.8 ± 2.0 | ND |
a
Compound concentration that inhibited 50% of plaque formation, as determined by PRAs. Values are means ± SD of data derived from at least 3 independent experiments in duplicate.
b
GCV was used as a control for all strains except for PFArD100, for which FOS was used.
c
ND, not determined.